[go: up one dir, main page]

Liu et al., 2024 - Google Patents

Exogenous ephrin-A3 administration restores vaginal epithelial barrier function in progestin-treated mice

Liu et al., 2024

View PDF
Document ID
18170947255913762011
Author
Liu M
Miguel R
Aceves K
Cherpes T
Publication year
Publication venue
BioRxiv

External Links

Snippet

Desmosomes are junctional complexes that confer mechanical strength and enhance epithelial barrier function at mucosal surfaces by anchoring intermediate filaments to plasma membrane. While these roles are less explored in vaginal vs. cutaneous epithelium, we …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Huangfu et al. The IL-17 family in diseases: from bench to bedside
Etzerodt et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer
Kim et al. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis
Matsuo et al. CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer
WO2018231762A1 (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
Iida et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC chemokine ligand 3/macrophage inflammatory protein-1α
Lebratti et al. A sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection
US20160250315A1 (en) Human papilloma virus therapeutic vaccine
Wang et al. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor
Cheng et al. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Ni et al. Topical application of temperature-sensitive gel containing caerin 1.1 and 1.9 peptides on TC-1 Tumour-Bearing mice Induced High-Level Immune response in the Tumour Microenvironment
Han et al. CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
Liu et al. Exogenous ephrin-A3 administration restores vaginal epithelial barrier function in progestin-treated mice
TW201823471A (en) Methods of treating patients with a retinoic acid receptor-[alpha] agonist and an anti-CD38 antibody
Kii et al. STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model
JP2023503615A (en) Compositions and methods for treating diseases and conditions by depleting mitochondrial or genomic DNA from circulation
Liu et al. Exogenous ephrin-A3 reverses loss of vaginal epithelial barrier protection in progestin-treated mice
CN114848826B (en) Composition for treating pancreatic cancer, application and evaluation system
Hussein et al. Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation in vitro
Fan et al. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages
US11331269B2 (en) Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
US20180043008A1 (en) Recall antigen for promoting t-helper type 1 response
Goletz et al. Cell-based immunofluorescence test applying recombinant laminin 332 for the serological differential diagnosis of pemphigoid
Davis Investigation of the Pathophysiology and a Novel Therapeutic Target of Equine Asthma Syndrome
US20250282859A1 (en) Use of il-36 inhibitors for the treatment of netherton syndrome